Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation

Note: The present work has been carried out at the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.

• References

• 1 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 2 Boehringer-Ingelheim. Pradax - Product Monograph. 2012; 1-57. Available from: boehringer-ingelheim.ca/content/dam/internetopu/ca_EN/documents/humanhealth/prod-uct_monograph/Pradax-pm.pdf
• 3 Boehringer-Ingelheim. Highlight of prescribing information. 2014; 1-24. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccessViewServlet.ser?docBase=renetnt&folder-Path=/PrescribingInformation/PIs/Pradaxa/Pradaxa.pdf .
• 4 Reilly PA, Lehr T, Haertter S. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-328.
• 5 EMA. Pradaxa - Summary of product characteristics. 1-146. Available from: http://www.ema.eu ropa.eu/docs/en_GB/document_libraryEPAR_-_Product_Information/human/000829/WC500041059.pdf
• 6 Chang C, Bahadduri PM, Polli JE. et al. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006; 34: 1976-1984.
• 7 Providência R, Albenque J-P, Combes S. et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100: 324-335.
• 8 Lehr T, Haertter S, Liesenfeld K-H. et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012; 52: 1373-1378.
• 9 Härtter S, Sennewald R, Nehmiz G. et al. Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013; 75: 1053-1062.